A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder.

ABSTRACT: Alcohol Use Disorder (AUD) is a chronic relapsing disorder affecting an estimated 283 million individuals worldwide, with substantial health and economic consequences. Peroxisome proliferator-activated receptors (PPARs), particularly PPAR-α and PPAR-γ, have shown promise in preclinical studies as potential therapeutic targets for AUD. In this human laboratory study, we aimed to translate preclinical findings on the PPAR-α agonist fenofibrate to a human population with current AUD. We hypothesized that, relative to placebo, fenofibrate at the highest FDA-approved dose of 145 mg/d would attenuate responsiveness to in vivo alcohol cues in the lab and reduce drinking under natural conditions. However, the results did not show significant differences in craving and alcohol consumption be

SUBMITTER: Mason BJ 

PROVIDER: S-EPMC10825428 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature